Breaking News Instant updates and real-time market news.

NVS

Novartis

$75.68

0.13 (0.17%)

05:41
03/21/17
03/21
05:41
03/21/17
05:41

Novartis says Cosentyx may modify course of moderate-to- severe psoriasis

Novartis announced new data suggesting, for the first time, that Cosentyx may modify the course of moderate-to-severe psoriasis leading to long-term, treatment-free skin clearance. Cosentyx is the first and only IL-17A inhibitor to have reported this potential of disease modification. These data were presented at the 13th Annual Maui Derm for Dermatologists 2017, Maui, Hawaii at which Novartis presented 14 abstracts. Following one year of treatment with Cosentyx, patients were randomized to either continuous treatment or treatment cessation until relapse. Patients with continuous treatment maintained their high level of response. Among the patients that discontinued treatment, 21% of psoriasis patients maintained skin clearance for up to one year without treatment and 10% maintained skin clearance after two years without treatment. Patients with longer disease duration were more likely to relapse, suggesting that early intervention increases the chance of remaining relapse free.

  • 26

    Jun

NVS Novartis
$75.68

0.13 (0.17%)

03/14/17
LEER
03/14/17
NO CHANGE
LEER
Monitoring requests put Novartis Kisqali at marketing disadvantage, says Leerink
Leerink analyst Seamus Fernandez notes that Novartis (NVS) announced the FDA approval of its CDK4/6 inhibitor Kisqali in combination with an aromatase inhibitor for the first-line treatment of post-menopausal women with hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer. The analyst says that the label contains warnings for QT prolongation as well as liver toxicity, both of which necessitate frequent monitoring. Although Kisqali appears to have similar efficacy to Pfizer (PFE) approved Ibrance, the latter's label does not include these warnings or monitoring requirements, he points out, adding that he continues to see Ibrance maintaining long-term market dominance in the CDK4/6 class.
03/07/17
LEHM
03/07/17
NO CHANGE
LEHM
European Pharma raised to Positive from Neutral at Barclays
Barclays analyst Emmanuel Papadakis rolled out coverage of the European Pharmaceuticals space and upgraded his sector view to Positive from Neutral. The analyst has "high conviction that the recent transformational era of R&D innovation is set to continue," which he believes will allow the sector to retain pricing power. Papadakis put Overweight ratings on AstraZeneca (AZN), Roche (RHHBY) and Shire (SHPG), with Astra his top pick. The analyst put an Equal Weight rating on GlaxoSmithKline (GSK) and Underweight ratings on Sanofi (SNY), Novartis (NVS) and Novo Nordisk (NVO).
03/07/17
LEHM
03/07/17
INITIATION
LEHM
Underweight
Novartis reinstated with an Underweight at Barclays
Barclays analyst Emmanuel Papadakis reinstated Novo Nordisk with an Underweight rating.
03/07/17
SOCG
03/07/17
UPGRADE
SOCG
Buy
Novartis upgraded to Buy from Hold at Societe Generale

TODAY'S FREE FLY STORIES

18:25
03/27/17
03/27
18:25
03/27/17
18:25
Conference/Events
Federal Reserve Bank of Dallas President speaks on monetary policy »

Dallas Federal Reserve…

EEI

Ecology & Environment

$9.90

-0.1 (-1.00%)

18:19
03/27/17
03/27
18:19
03/27/17
18:19
Hot Stocks
Ecology & Environment board urges shareholders to vote for company's nominees »

Ecology and Environment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PDLI

PDL BioPharma

$2.05

0.07 (3.54%)

18:16
03/27/17
03/27
18:16
03/27/17
18:16
Hot Stocks
PDL BioPharma CFO discloses purchase of 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

18:15
03/27/17
03/27
18:15
03/27/17
18:15
General news
Breaking General news story  »

Dallas Federal Reserve…

RAVN

Raven

$29.75

0.45 (1.54%)

18:14
03/27/17
03/27
18:14
03/27/17
18:14
Hot Stocks
Raven CEO says 'entering fiscal year 2018 from a position of strength' »

"We are very pleased…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

RAVN

Raven

$29.75

0.45 (1.54%)

18:12
03/27/17
03/27
18:12
03/27/17
18:12
Hot Stocks
Breaking Hot Stocks news story on Raven »

Raven sees FY18 CapEx…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

RAVN

Raven

$29.75

0.45 (1.54%)

18:11
03/27/17
03/27
18:11
03/27/17
18:11
Earnings
Raven reports Q4 EPS 12c, consensus 15c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

OREX

Orexigen

$4.13

0.15 (3.77%)

18:05
03/27/17
03/27
18:05
03/27/17
18:05
Hot Stocks
Orexigen, Bruno reach distribution agreement for Mysimba »

Orexigen Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

HUN

Huntsman

$22.89

0.24 (1.06%)

18:01
03/27/17
03/27
18:01
03/27/17
18:01
Hot Stocks
Huntsman moves up after projecting Q1 adjusted EBITDA to rise YoY »

Shares of chemical maker…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

PFE

Pfizer

$34.18

0.18 (0.53%)

, BMY

Bristol-Myers

$56.04

0.15 (0.27%)

18:00
03/27/17
03/27
18:00
03/27/17
18:00
Hot Stocks
Credit Suisse analysis shows value in hypothetical Pfizer-Bristol merger »

Credit Suisse analysts…

PFE

Pfizer

$34.18

0.18 (0.53%)

BMY

Bristol-Myers

$56.04

0.15 (0.27%)

NVS

Novartis

$75.10

0.73 (0.98%)

GILD

Gilead

$67.50

-0.01 (-0.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Mar

  • 01

    Apr

  • 27

    Apr

  • 02

    May

  • 02

    May

  • 06

    Jun

  • 26

    Jun

  • 27

    Aug

VRX

Valeant

$10.81

0.06 (0.56%)

18:00
03/27/17
03/27
18:00
03/27/17
18:00
Periodicals
Ex-Valeant CEO Pearson sues company over unpaid compensation, WSJ says »

Former Valeant CEO Mike…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

  • 24

    Aug

DGLY

Digital Ally

$4.60

0.49 (11.92%)

, TASR

Taser

$22.47

-0.03 (-0.13%)

17:54
03/27/17
03/27
17:54
03/27/17
17:54
Earnings
Digital Ally reports Q4 adjusted EPS (63c), two estimates (20c) »

Reports Q4 revenue…

DGLY

Digital Ally

$4.60

0.49 (11.92%)

TASR

Taser

$22.47

-0.03 (-0.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

AEM

Agnico Eagle

$44.64

0.81 (1.85%)

17:51
03/27/17
03/27
17:51
03/27/17
17:51
Syndicate
Agnico Eagle to sell approximately 5M shares to institutional investor »

Agnico Eagle Mines…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 28

    Apr

  • 28

    Apr

HUN

Huntsman

$22.89

0.24 (1.06%)

17:50
03/27/17
03/27
17:50
03/27/17
17:50
Hot Stocks
Huntsman sees Q1 adjusted EBITDA to exceed the $274M reported in 1Q16 »

Huntsman Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

SELB

Selecta Biosciences

$11.92

-0.12 (-1.00%)

, RHT

Red Hat

$82.20

-0.76 (-0.92%)

17:43
03/27/17
03/27
17:43
03/27/17
17:43
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

SELB

Selecta Biosciences

$11.92

-0.12 (-1.00%)

RHT

Red Hat

$82.20

-0.76 (-0.92%)

SNX

SYNNEX

$118.32

1.38 (1.18%)

PSIX

Power Solutions

$6.40

0.07 (1.11%)

OCN

Ocwen

$4.89

0.08 (1.66%)

TSRO

Tesaro

$156.73

-3.27 (-2.04%)

DRI

Darden

$75.58

-1.13 (-1.47%)

FMSA

Fairmount Santrol

$6.74

-0.08 (-1.17%)

HCLP

Hi-Crush Partners

$15.40

0.05 (0.33%)

DECK

Deckers Brands

$56.51

0.23 (0.41%)

CYRX

Cryoport

$3.75

0.2219 (6.29%)

EVH

Evolent Health

$21.25

0.4 (1.92%)

STOR

STORE Capital

$23.46

-0.25 (-1.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 27

    Mar

  • 27

    Mar

  • 28

    Mar

  • 28

    Mar

  • 04

    Apr

  • 06

    Apr

  • 12

    Apr

  • 02

    May

  • 03

    May

  • 09

    May

  • 30

    Jun

ADHD

Alcobra

17:41
03/27/17
03/27
17:41
03/27/17
17:41
Hot Stocks
Brosh raises stake in Alcobra to 10.9% ahead of investor meeting »

Brosh Capital disclosed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

PSIX

Power Solutions

$6.40

0.07 (1.11%)

17:33
03/27/17
03/27
17:33
03/27/17
17:33
Hot Stocks
Weichai America to invest $60M in Power Solutions »

Power Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RADA

RADA Electronic

$1.15

-0.04 (-3.36%)

17:32
03/27/17
03/27
17:32
03/27/17
17:32
Syndicate
Breaking Syndicate news story on RADA Electronic »

RADA Electronic files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLV

iShares Silver Trust

$17.15

0.34 (2.02%)

17:29
03/27/17
03/27
17:29
03/27/17
17:29
Syndicate
Breaking Syndicate news story on iShares Silver Trust »

iShares Silver Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IAU

iShares Gold Trust

$12.08

0.07 (0.58%)

17:28
03/27/17
03/27
17:28
03/27/17
17:28
Syndicate
Breaking Syndicate news story on iShares Gold Trust »

iShares Gold Trust files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GABC

German American Bancorp

$44.33

-0.33 (-0.74%)

17:25
03/27/17
03/27
17:25
03/27/17
17:25
Hot Stocks
German American Bancorp announces 3-for-2 stock split »

German American Bancorp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STAF

Staffing 360 Solutions

$0.95

0.2215 (30.34%)

17:18
03/27/17
03/27
17:18
03/27/17
17:18
Hot Stocks
Staffing 360 Solutions, board reject buy-out offer from Jackson Investment Group »

Staffing 360 Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOS

Canada Goose

$15.40

-0.24 (-1.53%)

17:16
03/27/17
03/27
17:16
03/27/17
17:16
Hot Stocks
Breaking Hot Stocks news story on Canada Goose »

Adage Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$140.32

-0.02 (-0.01%)

, AAPL

Apple

$140.88

0.24 (0.17%)

17:14
03/27/17
03/27
17:14
03/27/17
17:14
Periodicals
Facebook hires Apple vet to lead Oculus hardware efforts, Bloomberg says »

Facebook (FB) has hired…

FB

Facebook

$140.32

-0.02 (-0.01%)

AAPL

Apple

$140.88

0.24 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 28

    Mar

ISTR

Investar Holding

$22.15

0.1 (0.45%)

17:13
03/27/17
03/27
17:13
03/27/17
17:13
Hot Stocks
Breaking Hot Stocks news story on Investar Holding »

EJF Capital reports 6.2%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.